Heron Therapeutics Welcomes Michael Kaseta to Its Board
Heron Therapeutics, Inc. (NASDAQ: HRTX), a forward-thinking biotechnology company, recently made a significant announcement regarding its leadership. The organization is pleased to share the addition of Michael Kaseta to its Board of Directors. His vast experience in corporate finance and business strategy is set to enhance Heron’s mission of improving patient care through innovative therapies.
Introducing Michael Kaseta
Michael Kaseta comes with a solid background and an impressive track record in the biopharmaceutical industry. Currently serving as the Chief Financial Officer and Chief Operating Officer at Liquidia Corporation, he plays a pivotal role in leading a company dedicated to creating treatments for rare cardiopulmonary diseases. His previous experience includes key financial positions at Aerami Therapeutics and Aralez Pharmaceuticals. His tenure at Sanofi S.A. is particularly notable, where he held a variety of financial roles, ultimately leading to the Chief Financial Officer position at Sanofi North America.
Expertise that Matters
Mr. Kaseta's extensive experience spans both large pharmaceutical corporations and smaller biotech firms. His capacity to manage significant financial operations, including overseeing a $10 billion business, showcases his competence and strategic insight. His appointment to Heron’s Board is expected to foster insights that will guide the company’s growth and product development strategies.
Reflections from the CEO
Craig Collard, Heron’s Chief Executive Officer, expressed enthusiasm regarding Mr. Kaseta’s appointment. He noted the value that Mike’s unique skill set brings to the company, highlighting that his experience will be crucial as Heron continues to drive innovation and push for the development of proprietary products that aim to enhance patient lives.
About Heron Therapeutics
Heron Therapeutics, Inc. is committed to pioneering advancements in medical treatments. The company focuses on developing and commercializing therapies that redefine the standard of care, specifically for patients in acute healthcare and oncology. Their dedication to innovation and scientific excellence positions Heron at the forefront of the biotechnology field, making significant impacts in patients' lives.
Contact Information for Inquiries
For those interested in more information or inquiries, Ira Duarte, Executive Vice President and Chief Financial Officer at Heron Therapeutics, is available at 858-251-4400 or via email at iduarte@herontx.com.
Frequently Asked Questions
Who is Michael Kaseta?
Michael Kaseta is the newly appointed member of the Board of Directors at Heron Therapeutics, with a wealth of experience in corporate finance and biotechnology.
What role does Michael Kaseta currently hold?
He is currently the Chief Financial Officer and Chief Operating Officer at Liquidia Corporation, focusing on innovative therapies for cardiopulmonary diseases.
What is Heron Therapeutics known for?
Heron Therapeutics specializes in developing and commercializing therapies that improve the standard of care for patients, particularly in acute care and oncology.
How does Heron Therapeutics plan to grow?
With the addition of experienced members like Michael Kaseta, Heron aims to continue driving innovation and expanding its portfolio of proprietary products.
Who can I contact for investor relations at Heron Therapeutics?
Ira Duarte serves as the Executive Vice President and Chief Financial Officer, and can be contacted for investor relations inquiries.
